![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Kurreck, A.; Geissler, M.; Martens, U. M.; Riera-Knorrenschild, J.; Greeve, J.; Florschütz, A.; Wessendorf, S.; Ettrich, T.; Kanzler, S.; Nörenberg, D.; Seidensticker, M.; Held, S.; Buechner-Steudel, P.; Atzpodien, J.; Heinemann, V.; Stintzing, S.; Seufferlein, T.; Tannapfel, A.; Reinacher-Schick, A. C. und Modest, D. P.
(2020):
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
In: Journal of Cancer Research and Clinical Oncology, Bd. 146, Nr. 10: S. 2681-2691
Herold, M.; Hoster, E.; Unterhalt, M.; Hänel, M.; Prange-Krex, G.; Forstpointner, R.; Florschütz, A.; Gräven, U.; Frickhofen, N.; Wulf, G.; Lengfelder, E.; Lerchenmüller, C.; Schlag, R.; Dierlamm, J.; Fischer von Weikersthal, L.; Ahmed, A.; Harich, H.-D.; Rosenwald, A.; Klapper, W.; Dreyling, M. und Hiddemann, W.
(2017):
Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomized trial of GLSG and OSHO.
In: Oncology Research and Treatment, Bd. 40: S. 74
Geissler, M.; Martens, U.; Knorrenschild, J. R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Mönnich, H.; Ettrich, T.; Kanzler, S.; Büchner-Steudel, P.; Heinemann, V.; Held, S.; Reinacher-Schick, A.; Hebart, H.; Atzpodien, J.; Egger, M.; Lindig, U. und Müller, C.
(2017):
mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Oncology Research and Treatment, Bd. 40: S. 123
Geissler, M.; Martens, U. M.; Knorrenschield, R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Wessendorf, S.; Seufferlein, T.; Kanzler, S.; Heinemann, V.; Held, S. und Reinacher-Schick, A.
(2017):
mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Annals of Oncology, Bd. 28
Davies, A.; Trask, P.; Demeter, J.; Florschütz, A.; Hänel, M.; Hong, X.; Kinoshita, T.; Pettengell, R.; Quach, H.; Robinson, S.; Sadullah, S.; Sancho, J.-M.; Udvardy, M.; Witzens-Harig, M.; Rufibach, K.; Zeuner, H. und Unterhalt, M.
(2017):
Health-Related Quality Of Life Results From The Phase III Gallium Study Of Obinutuzumab-Based And Rituximab-Based Therapy In Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.
In: Haematologica, Bd. 102: S. 190-191